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AbstrAct
Introduction: the functioning of the healthcare industry in any country is impossible without providing enough medicines for patient care. This problem can 
best be resolved only when the majority of drugs, especially vital, will be made at national plants (industry). In this context, competition from generic drugs 
is the most optimal strategy to reduce drug’s prices.
Aim: the paper should examine how the legal regime of intellectual property affects the availability of medicines for people and identify ways of supporting 
breakthrough inventions and counter «unreal innovations».
Materials and methods: for the purpose of study were generalized information from the scientific journals of medical and legal perspective, monographs 
by using a set of scientific methods. Namely under systematic approach have been analyzed the problems of pharmaceutical market, ways of producing 
generic and original drugs. Comparative legal method was useful for learning features of flexible mechanisms of the TRIPS Agreement and market regulation 
of medicines in the world.
Results: based on the research was found that developed countries with strong pharmaceutical industry are interested in maximizing the protection of 
intellectual property rights, including importing countries. Flexible mechanisms of the TRIPS Agreement can be useful for developing countries.
Conclusions: thus, successful development of pharmaceutical industry and health care should be accompanied by the following measures: - improvement of 
public health must be recognized as a main task of government policy; - substantial state support aimed at increasing the availability of drugs in the domestic 
market and the strengthening of export potential; - decrease patent protection of medicines and stimulate market launch of generic copies.
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Wiad Lek 2016, 69, 3 (cz. II), 587-591
InTROducTIOn
The functioning of the healthcare industry in any country 
is impossible without providing enough medicines for patient 
care. In other words, medical institutions and citizens should be 
provided with affordable and quality medicines. This problem 
can best be resolved only when the majority of drugs, especially 
vital, will be made at national plants (industry).
The researchers write that the health is a fundamental human 
right and essential medicines are required to maintain it. Therefore it 
is morally unjust and unethical to compromise access to medicines 
for commercial interests. Pharmaceutical companies actually use 
patents to stifle competition, increase price and create monopolies. 
Thus they make thrice the profit of other companies and have 
remained the most profitable business in USA since 1982. Generic 
competition is the best strategy of lowering drug prices. Anti-
retrovirals (ARv) prices reduced from $ 10,000 to 136 USD per 
patient per year with supply of generics from India [1].
Globalization (opening of the borders) complicated processes 
of manufacturing and trade, when many economies faced the 
problem that domestic production became unprofitable versus 
imports. Although a competitive advantage in trading gained 
through various ways, in XX-XXI centuries intellectual property 
began to play an important role. Scientists say that innovation 
is the key driver in the modern economy [2].
International agreements governing these relations, above all, 
protect the interests of developed countries that produce innovative 
products. Accession to TRIPS in 1995 however has changed the 
whole scenario. To mitigate the potential negative effect of drug 
patents such as increase in drugs price, certain flexibilities have 
been provided in TRIPS which have been utilized by the member 
countries [2]. However, these agreements contain so-called flexible 
mechanisms aimed at protecting the interests of underdeveloped 
countries. These countries mainly import medicines and reduce 
the legal protection of intellectual property. The TRIPS agreement 
also leaves space to deal with the national level issues and process 
of executing TRIPS obligations [3]. 
AIM
The paper should examine how the legal regime of intellectual 
property affects availability of medicines for people and identify 
ways of supporting breakthrough inventions and counter «unreal 
innovations».
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MATERIALS And METHOdS
Globalization has turned the world into a global village of 
interdependent countries linked by multilateral agreements 
like the «Trade Related aspects of Intellectual Property rights 
(TRIPS) agreement» of the World Trade Organizations (WTO). 
However, there is concern in Low Income Countries and Low-
Medium Income Countries that this agreement may further 
reduce the people’s access to much needed essential drugs. This 
may ultimately increase morbidity and mortality indices and 
will worsen their health and economic status and lead to under-
development [1].
Today there are the following dominant trends in the global 
pharmaceutical market: (1) reducing the share of the branded 
drugs in the total world market and expiration of patents on 
them. It will lead the entry of generic products and lower prices 
on them; (2) reducing the cost of drugs in the United States 
and increased demand on medicines in emerging markets; 
(3) a new drugs that will create entirely new possibilities of 
drug exposure, will appear at the market. For example, this is 
medication for the treatment of multiple sclerosis, metastatic 
melanoma, the vaccine against prostate cancer and certainly 
a biosimilars; (4) more active using of utility medicaments, in 
particular generic. For example, in Japan, where the market for 
many years had an absolute advantage of branded drugs, in recent 
years the state policy is the transfer of 40% of the population in 
the generic drugs. This is due to the fact that health care around 
the world fall into a vicious circle: the higher health care costs 
lead the greater life expectancy; the greater life expectancy - 
the higher health care costs; (5) the growing concentration of 
pharmaceutical companies; (6) the deepening of specialization 
of the pharmaceutical business (marketing, production and 
wholesale); (7) active application of the flexible mechanisms of 
the WTO by the importing countries, import substitution of 
strategically important medicines, vital and essential medicines, 
medical products and equipment.
As you know, the crisis in public health, especially in the 
field of HIv, tuberculosis and malaria, has led to the adoption of 
the 2001 WHO Ministerial Council Declaration on the TRIPS 
Agreement and Public Health (Doha Declaration). The Doha 
Declaration reaffirmed that the TRIPS Agreement contains 
flexibilities that could be used by member countries to increase 
access to medicines.
Enforcing patent rights and enticing developing countries to 
make TRIP-plus agreements will worsen their health and economic 
status and lead to under-development. This is not the aim of 
globalization which promises trade liberalization and technology 
transfer. Countries should be able to use TRIPS flexibilities and 
adapt patent laws according to national realities without fear 
of sanctions. It is surprising that developed countries like the 
USA will grant aid through PEPFAR and Global Fund and still 
encourage loss of human capital through unaffordable essential 
drugs, this can only perpetuate the poverty cycle [1].
We can not agree with the opinion of prof. A. Pearman: «All 
production has its own specifics, but some have even more than 
others, and pharmaceuticals just refer to this category» [4]. This 
strategically important technology sector can be characterized by 
a high level of income and a limited number of participants. The 
development of new drugs is impossible without considerable 
investments, often a significant portion of these costs reimburse 
the government or insurance companies. In addition, countries 
try to endeavor to maintain the possibility to influence on the 
functioning of the pharmaceutical market in order to ensure 
the competitiveness of domestic producers.
As you know, medicines are supported for the treatment or 
prevention of diseases, pregnancy prevention, rehabilitation, 
correction or changes in physiological functions in humans, 
and is the subject of a thorough public control at all stages 
of their market turnover. The pharmaceutical market can be 
characterized by the following features: significant investments 
in research and development; a wide range of products; long 
cycle developments; high research intensity; inelastic demand, 
its dependence on epidemics and natural disasters; monopolistic 
tendencies in the market; the sole need of mankind to maintain 
health, increase life expectancy; similarities in different countries 
of the dynamics and prevalence of major diseases.
A special place occupies the problem of legal protection of 
intellectual property rights, which were used in the creation 
of medicines. A special regime of intellectual property rights 
ensures the protection of the commercial interests of developers 
and investors.
The TRIPS Agreement covers seven forms of intellectual 
property, namely, patent, copyright, trademark, industrial design, 
geographical indication, lay out design of integrated circuit, 
and protection of undisclosed information or trade secrets. 
Pharmaceutical patents can be classified under the following 
categories: (1) Drug compound patents; (2) Formulation / 
composition Patents; (3) Synergistic combination Patents; (4) 
Technology Patents; (5) Polymorph Patents; (6) Biotechnology 
patents; (7) Process patents [5].
Patenting system as the most common and effective means of 
legal protection of innovative facilities in respect of pharmaceutical 
products is controversial. The Pharma industry is one of the most 
intense «knowledge driven» sectors. Pharmaceutical research 
is very costly and unpredictable in nature [5].
On the one hand, monopolists maximize their profits by 
significantly raising the price of the product, because of economic 
and legal nature of patenting. The profitability of the difference 
in prices and production costs are high, despite the fact that the 
high prices reduces the number of buyers. This is because the 
full development and clinical trials of new drug cost an average 
of $ 1 billion USA [6]. Complete series of synthesis, testing and 
release new drug to the market is nearly 10 – 16 years. 
On the other hand, patent owners often abuse by exclusive 
rights: - among 50 - 60 drugs that appear at the market, two-
thirds of them are aimed at people who does not suffer from the 
most common diseases; - along with the increasing complexity 
of technology and the simplification of their use, especially 
noticeable improvements of attractiveness of medicines; - new 
generation of effective drugs which are intended for treating 
of diseases of mass, so-called «blockbuster» appear less and 
less, while pharmaceutical companies bring to the market 
for 2 - 3 drugs to replace drugs, the validity of patents on 
which have expired [7]; - for patented medicines are set high 
prices, making modern and effective drugs available for the 
vast majority. For example, in 2001 the US wholesale price 
for popular drug «Prozac» company «Pfizer» has fallen from 
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$ 240 USA to less than $ 5 USA during 6 months since the 
end of the patent [8].
Strong intellectual property rights protection checks imitations 
while simultaneously attempt to strengthening the ownership 
of the innovation. It also has a positive effect on economic 
growth by increasing the average duration of monopoly on 
power of goods and an increase in the average price of goods 
in the economy [9]. But clearly we can not agree with this 
statement: strong intellectual property protection satisfies the 
interests of exporters of innovations contrary to the interests 
of importers.
According to this, we should pay attention to the main flexible 
mechanisms of the TRIPS Agreement. Namely, regulation of the 
sphere of patent protection, legal regimes of data exclusivity and 
parallel imports, additional conservation certificate, compulsory 
licensing etc.
In the TRIPS Agreement attached the general principle of total 
patent protection according to which patent protection can obtain 
an invention in any field of technology that goes for products 
and processes. Certainly it has certain exceptions. According to 
Art. 27 of the TRIPS Agreement all inventions regardless of the 
field of technology would be eligible for protection [10]. 
By this time many states used a limited list of pharmaceutical 
and biotechnological inventions that could be patented, because 
the importer of innovation is always beneficial to establish 
maximum simplified intellectual property and vice versa. Now 
the task is no less important because of the problem of «evergreen 
patenting». 
India laws are the most effective to combat the world’s 
«evergreen patenting».
Section 3 of the Indian Patent Act 1970 has a list of the 
objects that can not be considered as «invention» and therefore 
it is impossible to obtain a patent on them. Firstly, section 
3 (d), even before the amendments of 2005, excluded the 
possibility to obtain a patent for an existing drug, which new 
actions or new uses have been identified. Therefore, new ways 
to use old products can not be patented in India. Secondly, 
section 3 (d) clearly decides that the opening of the new forms 
of existing drugs is not an invention, excepting the situations 
when the effectiveness of the drug is significantly higher than 
the previously known substances. Thirdly, Section 3 (e) states 
that it is impossible to obtain a patent for an impurity, if it is 
only necessary to connect the properties of the components. 
Interestingly, India has also made changes in the definition 
of inventive step, to make it more stringent. Section 2 (1) (ja) 
requires the bearer of the patent to show that the invention has a 
technical advantage or economic importance, or a combination 
of both. The Patent Law also includes procedural safeguards 
to prevent unjustified patenting and allows any person to 
protest the patent. 
Also, there are several ways how to challenge a patent after 
its issuance. Firstly, contesting of the patent may be filed within 
one year from the date of granting of the patent. Secondly, the 
procedure for cancellation of the patent can be started at any 
time after its issuance. Thus, the Indian patent law contains some 
leverages to prevent unjustified patenting. It shows how strictly 
the Indian Patent Office applies the patent standards to protect 
public health from the harmful effects of unwarranted patents.
So, India has used flexibilities such as compulsory license 
grant provision during health crisis; scope to redefine standards 
for patentability and Section 3(d) antiever- greening provision 
that restricts patenting on incremental innovation. Section 3(d) 
In order to safeguard the interest of the public and to maintain 
a balance for the accessibility of life saving drugs to patients 
(public goods), The Indian Patents Act, 1970 (amended) has 
stipulated various provisions (exceptions) making patentable 
subject matter non-patentable. That is why Pharma giants are 
not in favor of Section 3(d) and argue that Section 3(d) stands 
in the way of innovation [2].
That is why Pharma giants are not in favor of Section 3 (d) 
and argue that Section 3 (d) stands in the way of innovation [2]. 
But we can not agree with this opinion, because pharmaceutical 
manufacturers get substantial profit, while medicines are inaccessible 
for most citizens. Also, holders often abuse their patents for 
as long keeping a monopoly on technology and prevent the 
emergence of competitors.
Moreover, Indian Medicinal Products Act reduces to almost 
zero the likelihood that multinational companies will be able to 
prevent the entry of new drugs on the Indian market. According 
to Indian law, even if the multinational pharmaceutical companies 
would not register the drug in the country, India will still be 
possible to submit its generic version. One of the provisions in the 
Indian Act allows Indian medicines regulatory agency authorize 
generic versions of the drugs for trading in confirming their 
bioequivalence with the drug, that has been already approved. 
For drugs that have already been presented on the world market, 
but has not yet been registered by the manufacturer for sale in 
India, the decision of the Indian regulatory Medicines Agency 
may be based on the resolution of trade, issued in other countries, 
defining the level of safety and efficacy. In the past, already there 
were cases when a generic version of the drug was introduced 
in India even earlier than the original.
We should mention some legal measures of how to extend 
patent protection (extra security certificate).
The products designed to protect health, may be subject to 
administrative procedure for permission before they can be 
released on the market. Therefore, the amount of time that passes 
from the filing date of the patent to obtaining permission on 
producing the first product on the market, can reduce the period 
of effective protection under the patent. In this regard, there is a 
need to provide additional protection for original medicines. As 
you know, clinical trials and registration of medicines can last 
for years and even if patents were obtained in the initial stages 
of preparations, the term of their action often comes to an end 
when the product only appears on the market.
Typically, the institute of additional security certificate 
establishes in legislation as follows: «A further period of 
protection for a medicinal protection product which is protected 
by a patent and which has been subject to an administrative 
authorisation procedure, the period that elapses between the 
filing of the application for a patent and the first authorisation 
to place the product on their respective market, as defined 
for that purpose by the relevant legislation, may shorten the 
period of effective protection under the patent. This sets 
the maximum length of the extension, for example, from 5 
to 15 years». 
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Also laws of different countries provide an additional six-
month extension of the period of patent protection if pediatric 
studies were performed relating to medicinal products, the 
results of which are reflected in the information about the 
product.
In this context, it should be considered an exception to the 
purpose of the introduction of generic medicines on the market. 
Art. 33 of the TRIPS Agreement stipulates that the term of the 
patent protection should not end before the expiration of twenty 
years from the filing date for a patent. For manufacturers of 
generics and patients who expect cheap essential medicines, it is 
important to bring medicines on the market as soon as possible 
after the 20 year period of patent protection. According to this 
number of developed countries, such as Canada, enshrined in 
law so-called «Bolar exception» that allows the use of a patented 
invention for the purpose of registering generic to the actual 
expiration of the patent, without the need to obtain the permission 
of the patent owner. 
RESuLTS End dIScuSIOn 
Highly developed countries with a strong pharmaceutical 
industry are interested in maximum protection of intellectual 
property rights, including in countries of import. Developing 
countries should use flexible mechanisms of the TRIPS Agreement 
to provide citizens with affordable medicines and encourage 
investors in localization their companies in the state.
TRIPS Agreement provides the following exceptions to exclusive 
rights: (1) state has the right to take measures which are necessary 
to protect public health and nutrition in sectors of vital importance 
to their socio-economic and technological development, if such 
measures are consistent with the TRIPS Agreement; (2) state has 
the right to establish limited exceptions to the exclusive rights 
granted by a patent, if such exceptions will not significantly conflict 
with a normal exploitation of the patent and cause significant 
harm to the legitimate interests of the patent owner, taking into 
account the interests of third parties; (3) state has the right to 
prevent the patenting of inventions, the prohibition of commercial 
use of which is necessary for protection of public order or public 
morality, public life or health of humans, animals or plants or 
to prevent significant damage of environment; (4) state has the 
right not to recognize patentable diagnostic, therapeutic, surgical 
methods of treatment of animals and humans.
Thus, as a reason for the free use of the patented invention 
we can add its application to meet the immediate needs of the 
public by producing substances drugs, list of which would be 
approved by the government. It is also possible to prohibit 
the patenting of medicines for certain groups of essential 
disease.
Aim of the «Bolar exception» is to complete the regulatory 
approval for the use of a generic product before the patent expires, 
and also production and introduction of generic drugs into the 
market on the day of expiry of the patent. This exception meets 
the requirements of the WTO and applies to both domestic 
producers and importers.
cOncLuSIOnS 
Therefore, the successful development of the pharmaceutical 
industry should be accompanied by the following measures:
1) Ensure social orientation of the state because the right to 
life includes the right to health. It obliges the State to improve the 
public health, which must be the highest priority for the government 
as it relates to the very physical existence of society.
2) Ensure substantial public support, both aimed at improving 
the availability of medicines in the domestic market, and increasing 
the country’s export potential. We can distinguish such measures 
of state support: - government return entitles funds spent on the 
implementation of GMP and other international quality control 
standards (modernization of fixed assets); - compensation of 
cost for the promotion of products abroad; - support of national 
producers; - providing preferential loans (guaranteed by the 
government) for pharmaceutical organizations implementing 
investment projects on creation, reconstruction and technical 
re-equipment of production facilities; - exemption technologies, 
components and spare parts which use for building national 
production equipment from import customs, duties and vAT; - 
implementation of programs that offer affordable medicines by 
enhancing the public order; - providing the system of subsidies and 
benefits for those companies that successfully export medicines 
to other countries.
Such public support should be allocated solely on the basis of 
competition, rather than advance specific manual «promising» 
companies. The following pharmaceutical relations are attractive 
for investors: biotechnology, genetic engineering, new vaccines, 
improvement of the method of application of medicines, medical 
equipment.
It should pay attention to the common problems of the 
developing countries, for example: - national pharmaceutical 
manufacturers find more profitable investments in marketing 
and sales, rather than the development of new effective drugs; 
- pharmaceutical manufacturers invest no more than 1 – 2 % of 
their revenue (in the USA and Western Europe – 10 – 15 %) in 
research and development; - pharmaceutical industry depends 
on import of substances, although some countries have national 
chemical industry, scientific and educational sphere; - there is 
practically no training of highly qualified personnel for modern 
pharmaceutical industry and scientific research; - there are no 
developed mechanisms for the transfer of intellectual property, 
obtained for the budget, including public research institutes, 
small innovative firms. These participants ensure subsequent 
commercialization of new knowledge etc.
The level of public sector involvement should be increased and 
should not be limited to initiating basic research and development 
but should continue up to the stage of commercializing the 
drugs. Capacity will need to be built in the public sector. Some 
research institutes like Nigeria’s NIPRD need to be upgraded and 
get better funded to ensure cost-effectiveness. There should be 
increase in research grants given to researchers and institution; 
this can be raised from both public and private sources. This 
should be given through an equitable and transparent system. 
Corporate organizations should be made to contribute to R&D 
efforts and tax credits can be received for these. Individuals 
in countries with low drug taxes can be made to pay special 
R&D taxes [1].
3) Establish centers of biological products development, as the 
prospect to take a leading position on the market of biogenerics 
has substantial economic conditions: the cost of treatment per 
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patient with some biologics estimates in the hundreds of thousands 
of dollars per year. For example, the cost of the annual rate of 
the drug «Avastin», which is used in the treatment of collateral 
cancer is $ 100,000 USA. Output of some of these drugs under 
patent protection in the coming years will bring considerable 
profits to companies that will be able to re-create them in the 
form of biogenerics.
4) Compensate customer’s expenses (30 – 50 %) on the
organization of clinical trials on the territory of Ukraine.
5) Decrease patent protection of medicines and stimulate
market launch of generic copies.
6) It is necessary to provide high price competitiveness
(availability) of the national pharmaceutical products using 
the low cost of labor, the reduction of energy prices and taxes. 
That is, in general, would improve the investment climate, exploit 
the potential of the internal market (the economic aspect) and 
the protection of public health. 
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